about
Prime-boost immunization strategies against Chikungunya virusConsensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cellsNovel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporationA combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines.Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.Therapeutics and vaccines against chikungunya virus.Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.Oral delivery of plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to high doses.Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses.Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.Correction: Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes.A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity.Challenges of Global Vaccine Development.Cellular immunogenicity of novel gene immunogens in mice monitored by in vivo imaging.Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responsesIncreased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activityCombining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses
P50
Q24701774-90134522-E155-431E-AF15-F9B99535E5ECQ28487823-CFFF0A95-1BA9-4D7B-B143-724FE444432AQ34394530-A2C29ECF-D94B-4007-8FD6-4A5604341A7DQ35191236-587EE127-79E6-463B-9965-019CF113CA31Q36494079-82C0B795-3146-4860-AD34-D2CCA08A5E61Q37610683-78783EB0-2CAD-4185-B126-0A6D6707B9ECQ37711813-B08DCC47-856C-4A95-AF29-EBCCFF40048CQ38432812-A60BE366-D94B-4851-AB7C-F55FF4E8F1C8Q39981110-C451B567-1170-4A66-9DA6-C4851BC66F07Q42231366-7C8B3ECA-F991-4CF3-A09F-1246218650EBQ42411962-2C092744-0EED-4D94-A4E2-720363CAD843Q42533779-58355D47-03BD-4E73-94A4-C4201187C4DDQ42726161-DB348341-1D88-49F3-B676-53322C07E4CBQ43718972-B211A30D-9650-4747-82F2-5523E6BE0061Q44439908-5CF02FED-D2F8-4CA4-82A7-74626A3273B9Q46191593-EC4EDBEE-5521-4330-96D4-EF0B72B2DBF1Q46616093-9D6F3FC1-FC9F-464F-9518-C5BE366FFF99Q51076478-1643B34F-B1C6-4647-B317-5F8A62279B68Q53500177-9A95593A-354D-44B8-9B45-57ADE4E93E82Q54476337-3BD14DCC-CA04-463A-8BD1-B083AD36A585Q63382894-473E6443-D417-44CE-BA7B-C96B7292521EQ64129511-EAD43002-9829-4E15-9B96-ADD125BDB2E1Q64133522-86D0006D-C256-420C-BB5E-01150795BABA
P50
name
David Hallengärd
@en
type
label
David Hallengärd
@en
prefLabel
David Hallengärd
@en